Vonoprazan Dosing Recommendations
For adults with erosive esophagitis, use vonoprazan 20 mg once daily for healing and 10 mg once daily for maintenance; for H. pylori eradication, use 20 mg twice daily in combination regimens; and reduce to 10 mg once daily in patients with severe hepatic impairment (Child-Pugh Class B or C). 1
Dosing by Indication
Erosive Esophagitis (Healing)
- Standard dose: 20 mg once daily for 8 weeks 1
- Renal impairment (GFR <30 mL/min): Reduce to 10 mg once daily 1
- Hepatic impairment:
- Child-Pugh Class A: 20 mg once daily
- Child-Pugh Class B or C: 10 mg once daily 1
The 2024 AGA guidelines support vonoprazan as superior to PPIs specifically for severe erosive esophagitis (LA grade C/D), where vonoprazan 10-20 mg demonstrated 75-77% maintenance of healing versus 62% with lansoprazole 15 mg 2. For LA grade C/D erosive esophagitis, vonoprazan should be the preferred agent, particularly if PPIs fail to maintain healing 2.
Maintenance of Healed Erosive Esophagitis
- Standard dose: 10 mg once daily for up to 6 months 1
- No dose adjustment needed for renal or hepatic impairment 1
This lower maintenance dose (10 mg) proved superior to lansoprazole 15 mg in preventing recurrence of severe esophagitis, with recurrence rates of 5-13% versus 39% for LA grade C/D disease 2.
Non-Erosive GERD (Heartburn Relief)
- Standard dose: 10 mg once daily for 4 weeks 1
- No dose adjustment needed for renal or hepatic impairment 1
H. pylori Eradication
Vonoprazan should be used in place of PPIs for most patients with H. pylori infection 2, as it achieves 92% eradication rates versus 80% with PPIs 2.
Triple Therapy (Preferred)
- Vonoprazan 20 mg + amoxicillin 1,000 mg + clarithromycin 500 mg
- All given twice daily (morning and evening, 12 hours apart)
- Duration: 14 days 1
Dual Therapy (Alternative)
- Vonoprazan 20 mg twice daily + amoxicillin 1,000 mg three times daily
- Duration: 14 days 1
Dose adjustments for H. pylori treatment:
- Renal impairment (GFR <30 mL/min): Use is NOT recommended 1
- Hepatic impairment:
- Child-Pugh Class A: 20 mg twice daily
- Child-Pugh Class B or C: Use is NOT recommended 1
The twice-daily dosing for H. pylori is critical because it provides superior eradication in clarithromycin-resistant strains (66-70% versus 32% with PPIs) 2. Even a 7-day dual therapy regimen with vonoprazan 20 mg twice daily achieved 85% eradication rates 2.
Peptic Ulcer Disease
Vonoprazan should generally NOT be used as first-line therapy for PUD 2, given higher costs and lack of clear superiority over PPIs. However, vonoprazan 20 mg once daily for 6-8 weeks is noninferior to lansoprazole 30 mg for gastric and duodenal ulcer healing (94-96% healing rates) 2.
For secondary ulcer prophylaxis in high-risk patients (chronic aspirin or NSAID use with prior ulcer history), vonoprazan 10-20 mg once daily is noninferior to lansoprazole 15 mg 2.
Administration Considerations
- Timing: Can be taken with or without food (no meal timing requirement unlike PPIs) 1
- Swallow whole: Do not chew or crush tablets 1
- Missed doses:
- For GERD indications: Take within 12 hours; otherwise skip
- For H. pylori: Take within 4 hours; otherwise skip 1
Key Clinical Advantages
Vonoprazan provides more rapid and potent acid suppression than PPIs, achieving maximal acid suppression within 1 day versus 3-5 days for PPIs 2. The longer half-life (6-9 hours versus 1-2 hours) allows once-daily dosing without meal timing restrictions 2. Unlike PPIs, vonoprazan is not affected by CYP2C19 genetic polymorphisms, providing more consistent efficacy across populations 2.
Common Pitfalls to Avoid
- Do not use vonoprazan as first-line for mild erosive esophagitis (LA grade A/B) due to cost and similar efficacy to PPIs 2
- Do not use in severe renal impairment (GFR <30 mL/min) for H. pylori treatment 1
- Do not use in moderate-to-severe hepatic impairment (Child-Pugh B/C) for H. pylori treatment 1
- Reserve vonoprazan for PPI failures in confirmed GERD (LA grade B or greater, Barrett's esophagus, peptic stricture, or abnormal pH monitoring) 2